Shanghai Pharmaceuticals Holding Co Ltd (601607) - Total Liabilities
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) has total liabilities worth CN¥143.90 Billion CNY (≈ $21.06 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Pharmaceuticals Holding Co Ltd - Total Liabilities Trend (1994–2025)
This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 601607 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shanghai Pharmaceuticals Holding Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Pharmaceuticals Holding Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cencosud
SN:CENCOSUD
|
Chile | CL$9.59 Trillion |
|
Glaukos Corp
NYSE:GKOS
|
USA | $222.40 Million |
|
Osisko Gold Ro
TO:OR
|
Canada | CA$195.73 Million |
|
Noble Corporation plc
NYSE:NE
|
USA | $3.11 Billion |
|
Light & Wonder Inc
NASDAQ:LNW
|
USA | $5.79 Billion |
|
Unicaja Banco SA
MC:UNI
|
Spain | €91.34 Billion |
|
InterDigital Inc
NASDAQ:IDCC
|
USA | $967.11 Million |
|
Bank of Maharashtra
NSE:MAHABANK
|
India | Rs3.94 Trillion |
Liability Composition Analysis (1994–2025)
This chart breaks down Shanghai Pharmaceuticals Holding Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shanghai Pharmaceuticals Holding Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Pharmaceuticals Holding Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Pharmaceuticals Holding Co Ltd (1994–2025)
The table below shows the annual total liabilities of Shanghai Pharmaceuticals Holding Co Ltd from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥143.36 Billion ≈ $20.98 Billion |
+4.29% |
| 2024-12-31 | CN¥137.47 Billion ≈ $20.12 Billion |
+4.42% |
| 2023-12-31 | CN¥131.65 Billion ≈ $19.26 Billion |
+9.58% |
| 2022-12-31 | CN¥120.13 Billion ≈ $17.58 Billion |
+15.10% |
| 2021-12-31 | CN¥104.37 Billion ≈ $15.27 Billion |
+10.51% |
| 2020-12-31 | CN¥94.44 Billion ≈ $13.82 Billion |
+7.76% |
| 2019-12-31 | CN¥87.64 Billion ≈ $12.82 Billion |
+8.94% |
| 2018-12-31 | CN¥80.45 Billion ≈ $11.77 Billion |
+47.15% |
| 2017-12-31 | CN¥54.67 Billion ≈ $8.00 Billion |
+19.08% |
| 2016-12-31 | CN¥45.91 Billion ≈ $6.72 Billion |
+13.25% |
| 2015-12-31 | CN¥40.54 Billion ≈ $5.93 Billion |
+21.94% |
| 2014-12-31 | CN¥33.24 Billion ≈ $4.86 Billion |
+21.72% |
| 2013-12-31 | CN¥27.31 Billion ≈ $4.00 Billion |
+16.87% |
| 2012-12-31 | CN¥23.37 Billion ≈ $3.42 Billion |
+7.76% |
| 2011-12-31 | CN¥21.69 Billion ≈ $3.17 Billion |
+33.17% |
| 2010-12-31 | CN¥16.28 Billion ≈ $2.38 Billion |
+157.08% |
| 2009-12-31 | CN¥6.33 Billion ≈ $926.94 Million |
+11.80% |
| 2008-12-31 | CN¥5.67 Billion ≈ $829.08 Million |
+9.65% |
| 2007-12-31 | CN¥5.17 Billion ≈ $756.14 Million |
+12.05% |
| 2006-12-31 | CN¥4.61 Billion ≈ $674.83 Million |
+5.53% |
| 2005-12-31 | CN¥4.37 Billion ≈ $639.50 Million |
-0.75% |
| 2004-12-31 | CN¥4.40 Billion ≈ $644.31 Million |
+9.33% |
| 2003-12-31 | CN¥4.03 Billion ≈ $589.33 Million |
+18.34% |
| 2002-12-31 | CN¥3.40 Billion ≈ $498.00 Million |
+37.51% |
| 2001-12-31 | CN¥2.47 Billion ≈ $362.16 Million |
-2.94% |
| 2000-12-31 | CN¥2.55 Billion ≈ $373.14 Million |
+15.61% |
| 1999-12-31 | CN¥2.21 Billion ≈ $322.77 Million |
+16.23% |
| 1998-12-31 | CN¥1.90 Billion ≈ $277.71 Million |
+518.28% |
| 1997-12-31 | CN¥306.95 Million ≈ $44.92 Million |
-1.92% |
| 1996-12-31 | CN¥312.95 Million ≈ $45.79 Million |
+17.26% |
| 1995-12-31 | CN¥266.88 Million ≈ $39.05 Million |
+18.53% |
| 1994-12-31 | CN¥225.16 Million ≈ $32.95 Million |
-- |
About Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more